SG3 Management’s Cabaletta Bio CABA Stock Holding History

SG3 Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20,000	Closed	-$41K	–	467
2022 Q1	$41K	Hold	20,000	–	–	﹤0.01%	879
2021 Q4	$76K	Buy	+20,000	New	+$213K	﹤0.01%	927

Other funds holding CABA

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

SG3 Management's CABA Position: Q2 2022 in Review

SG3 Management sold out of Cabaletta Bio (CABA) in Q2 2022, closing a stake of 20,000 shares — an estimated $41K sold.

SG3 Management first reported a position in CABA in Q4 2021 and held it in 2 quarters. The position peaked at $76K in Q4 2021. 55 funds tracked by Wall St. Rank hold CABA as of Q2 2022.

SG3 Management reported no remaining Cabaletta Bio position as of Q2 2022 after selling out during the quarter.
SG3 Management sold 20,000 Cabaletta Bio shares in Q2 2022, an estimated $41K.
SG3 Management first reported a position in Cabaletta Bio in Q4 2021 and held it in 2 quarters.
SG3 Management's Cabaletta Bio position peaked at $76K in Q4 2021.
55 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.